Providing an oncology cell therapy reality check

Challenge: A venture capital investor needed a reality check on a clinical stage cancer biologic prior to a proposed $10m investment with a very short deadline.
Learn More

Providing biotech due diligence of a Phase lll oncology program

Challenge: A major pharmaceutical company asked us for support in the due diligence and assessment of a Phase III in-licensing opportunity. The drug in question had met its primary endpoint in a...
Learn More

Providing in-licensing due diligence

Challenge: A pharma company needed help conducting due diligence on an in-licensing/acquisition candidate for a Phase IIb respiratory drug.
Learn More

Valuation of drug discovery company with Monte Carlo simulation

Challenge: A drug discovery company preparing for a forthcoming funding round wanted to update a valuation of the business based on a series of contract research projects and the proprietary value in...
Learn More

Vendor due diligence of a regulatory dossier

Challenge: A biotech company with a novel oral drug delivery technology platform was looking to out-license its lead asset, a reformulated generic therapeutic in a new, non-opioid pain, indication,...
Learn More

Oncology due diligence

Challenge: Alacrita was engaged by a strategic investor to conduct initial due diligence on a new EGFR therapeutic strategy in oncology.
Learn More

Alzheimer's due diligence for strategic investor

Challenge:  Alacrita was engaged by a strategic investor to conduct initial due diligence on a novel observation and potential product opportunity in Alzheimer’s disease.
Learn More

Gene therapy manufacturing license negotiation

Challenge A private biotech company developing gene therapy products for several orphan diseases was in the process of initiating CMC development for their pipeline products. In order to move...
Learn More

Due diligence on generic therapeutic

Challenge A private investment firm was seeking an independent reality-check on a potential investment in a pharmaceutical company that had recently in-licensed a generic therapeutic asset. The firm...
Learn More

New in-licensing opportunities in inflammation

Challenge A small molecule pharmaceutical incubator is using a novel and proprietary drug discovery and translational platform to develop first-in-class, small molecule therapeutics for the treatment...
Learn More

Sourcing licensing opportunities in oncology & other therapeutic areas

Alacrita provides both in- and out-licensing support to a number of pharmaceutical and biotech organizations and companies. Below you'll find a series of case studies related to this service. 
Learn More

Dermatology due diligence and valuation

Challenge Alacrita’s pharma consultants were engaged to conduct a due diligence and valuation of a Phase II dermatology asset.
Learn More
Content not found